Odyssey Therapeutics (NASDAQ:ODTX) Price Target Raised to $29.00

Odyssey Therapeutics (NASDAQ:ODTX) had its price target boosted by analysts at JPMorgan Chase & Co. from $26.00 to $29.00 in a research report issued to clients and investors on Friday,Benzinga reports. The brokerage presently has an “overweight” rating on the stock. JPMorgan Chase & Co.‘s target price points to a potential upside of 32.12% from the stock’s previous close.

Several other equities analysts also recently commented on ODTX. TD Cowen began coverage on shares of Odyssey Therapeutics in a research note on Tuesday, June 2nd. They set a “buy” rating for the company. Zacks Research raised Odyssey Therapeutics to a “hold” rating in a research note on Wednesday, June 3rd. Wall Street Zen downgraded Odyssey Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, June 20th. Oppenheimer reaffirmed an “outperform” rating and set a $40.00 price target on shares of Odyssey Therapeutics in a research report on Thursday, June 18th. Finally, Wedbush began coverage on Odyssey Therapeutics in a report on Tuesday, June 2nd. They issued an “outperform” rating and a $30.00 price objective for the company. Five investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $33.00.

Odyssey Therapeutics Stock Up 1.9%

Shares of NASDAQ ODTX traded up $0.40 during mid-day trading on Friday, hitting $21.95. The stock had a trading volume of 20,771 shares, compared to its average volume of 313,121. Odyssey Therapeutics has a 1 year low of $15.10 and a 1 year high of $22.26. The business’s 50 day moving average price is $17.78.

Odyssey Therapeutics (NASDAQ:ODTX) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.74) earnings per share for the quarter. Equities research analysts anticipate that Odyssey Therapeutics will post -4.89 earnings per share for the current year.

Insider Buying and Selling at Odyssey Therapeutics

In other Odyssey Therapeutics news, Director Shelley Chu bought 11,111 shares of the stock in a transaction dated Monday, May 11th. The stock was purchased at an average cost of $18.00 per share, for a total transaction of $199,998.00. Following the completion of the acquisition, the director owned 11,111 shares of the company’s stock, valued at approximately $199,998. This trade represents a ? increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Nan (Ln) Li purchased 1,111,111 shares of the company’s stock in a transaction dated Monday, May 11th. The stock was bought at an average cost of $18.00 per share, for a total transaction of $19,999,998.00. Following the completion of the transaction, the director owned 3,333,516 shares in the company, valued at approximately $60,003,288. This represents a 50.00% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. Insiders have purchased 3,066,666 shares of company stock valued at $55,199,988 in the last quarter.

About Odyssey Therapeutics

Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines which are designed to precisely target disease pathology. Odyssey Therapeutics Inc is based in BOSTON.